-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：我們將WAT的12個月目標價從335美元上調至370美元，基於2026年每股收益預期14.50美元（高於先前預期的14.39美元；2027年每股收益預期下調0.05美元至16.34美元）的25.5倍市盈率。該目標價低於WAT過去三年和五年的平均預期本益比26.3倍和27.4倍。我們認為學術界/政府終端市場持續疲軟。此外，我們也注意到中國（多家美國生命科學工具和服務公司的重要市場）持續面臨政策挑戰，包括中國診斷相關分組（DRG）報銷政策更新對免疫診斷業務的不利影響。儘管WAT能否充分實現BDX交易的預期綜效仍存在不確定性，但我們認為其第一季業績令人鼓舞。收購的生物科學和診斷解決方案業務自交易完成以來已創造 5.2 億美元的收入，比預期高出 4,000 萬美元，較 2025 年第四季實現了顯著的環比增長。值得注意的是，生物科學部門以完整季度備考基準計算，銷售額僅下降了 1%，而 2025 年第四季則下降了 10%。
Related Articles
Mining & Metals
Earnings Flash (KBL.TO) K-Bro Linen Reports Q1 Revenue $139.1M, Up 52.9% YoY
$KBL.TO
Equities
Occidental Petroleum Q1 Adjusted Earnings Rise, Revenue Falls
Occidental Petroleum (OXY) reported Q1 adjusted earnings late Tuesday of $1.06 per diluted share, up from $0.87 a year earlier.Analysts polled by FactSet expected $0.60.Revenue for the three months ended March 31 was $5.23 billion, down from $5.70 billion a year earlier.Analysts surveyed by FactSet expected $5.44 billion.
$OXY
Mining & Metals
Curaleaf Swings to Q1 Profit As Revenues Beat Expectations
Curaleaf (CURA.TO) reported a swing to a surprise first-quarter profit, boosted by better than expected revenues.The company reported net income from continuing operations of US$70.1 million, or US$0.09 per share, compared with a loss of US$50.1 million, or a loss of US$0.09 per share. Analysts polled by FactSet had forecast a loss of US$0.08 per share.Revenue climbed 6% over the same period, to US$324 million, beating the US$317 million forecast."The macro headwinds that constrained growth over the past three years are now beginning to turn into meaningful tailwinds. Moreover, the historic rescheduling of medical cannabis provides a shift in the trajectory of our business and the industry overall, for which we are well-positioned," said chief executive Boris Jordan. "The investments we've made in the core pillars of our "Built for Growth" strategy are translating directly into tangible performance," he added.Curaleaf shares closed up $0.28, to $4.73 on Tuesday on the Toronto Stock Exchange.
$CURA.TO$HMMJ.TO